Demystifying clinical trial efficiency

Now more than ever developers--from the biggest pharma company to the smallest start-up--have to keep an eye oMaureen Martino, FierceBiotech Managing Editorn spending. As drugmakers battle ever-rising R&D costs, programs requiring years of clinical-stage work and massive budgets must be streamlined to cut waste and increase the chances of success. Achieving faster, more efficient clinical trials has become Holy Grail of drug development.

Join FierceBiotech Editor-in-Chief John Carroll at 2 p.m. EST on December 15th for our upcoming webinar on efficient clinical trial design and execution. He'll be accompanied by Neil Bodick, who set up Eli Lilly's early-stage Chorus development group, and Ken Getz, Tufts' clinical trial expert at the Center for the Study of Drug Development. Our expert panel will explore adaptive trials, next-gen biomarker screening, and integrated electronic data solutions and help you capitalize on the cutting-edge trends transforming the drug R&D world.

Anyone running a trial or planning to launch one will find this a valuable experience. Sign up now to take advantage of the $79 early-bird rate; after December 4th registration will cost $109. Click here to register.

Suggested Articles

Shorla Pharma picked up $8.3 million to push its cancer programs through U.S. regulatory approval and gear up for its first drug launch in 2021.

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.